On February 1, 2022 Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) reported that it will report its fourth quarter and full year 2021 financial results on Tuesday, February 8, 2022 (Press release, Deciphera Pharmaceuticals, FEB 1, 2022, View Source [SID1234607560]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET on Tuesday, February 8, 2022, to discuss the Company’s financial results and provide a corporate update.

The conference call may be accessed by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) and referring to conference ID 8293127. A webcast of the conference call will be available in the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source The archived webcast will be available on the Company’s website approximately two hours after the conference call and will be available for 30 days following the call.

On February 1, 2022 SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, reported that management will present at the following upcoming investor conferences (Press release, SpringWorks Therapeutics, FEB 1, 2022, View Source [SID1234607577]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2022 Guggenheim Oncology Conference on Thursday, February 10 from 10:00-10:25 am ET.
Cowen 42nd Annual Health Care Conference on Monday, March 7 from 1:30-2:00 pm ET.
Barclays Global Healthcare Conference on Wednesday, March 16 from 9:30-10:00 am ET.
Webcasts of these events will be available on the Events & Presentations page within the Investors & Media section of the company’s website at View Source Replays of the webcasts will be available on SpringWorks’ website for a limited time following each conference.

On February 1, 2022 FIMECS, Inc. (CEO: Yusuke Tominari, Ph.D., "FIMECS") a private biotechnology company creating a new class of drugs based on targeted protein degradation, reported that FIMECS has entered into a research collaboration with Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") on small molecule protein degraders against multiple targets for a multi-year period (Press release, FIMECS, FEB 1, 2022, View Source [SID1234630696]). The collaboration will leverage FIMECS’ expertise in targeted protein degradation and its proprietary RaPPIDS platform and Astellas’ scientific, regulatory, and clinical capabilities to accelerate the development of life-saving medicines to patients around the world.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, FIMECS will conduct research activities on multiple targets and Astellas will advance candidates for development and potential commercialization. Upon designation of a clinical development candidate, Astellas has the option to exclusively license degrader molecules against the designated target. FIMECS will receive an upfront payment and funding to support Astellas-related research. Additionally, FIMECS could earn from potential payments based upon the successful achievement of specified research, development, regulatory, and commercial milestones for all the targets initially selected by Astellas. In addition, FIMECS will receive single digit tiered royalties on future net sales on any products that may result from this collaboration. Astellas may, at its discretion, elect to expand the collaboration to include additional disease targets. This decision would trigger an additional one-time payment, as well as potential payment of milestones and royalties on a product-by-product basis.

"We are thrilled to partner with Japanese top-tier global pharmaceutical company, Astellas to combine their deep understanding of biology and strong clinical development capabilities with FIMECS’ proprietary protein degrader platform," said Yusuke Tominari, Ph.D., CEO, FIMECS. "We have already identified unique E3 ligase binders and established highly effective synthetic method as a degrader discovery platform, RaPPIDS. We are very pleased that our platform has been wellreceived by the organization. This strategic partnership will broaden the application of targeted protein degradation to address diseases with high unmet medical needs. We hope to continue this collaboration with Astellas with the goal of potentially delivering life-saving medicines to patients all over the world."

On February 1, 2022 Dr. Reddy’s Laboratories Ltd. along with its subsidiaries together referred to as "Dr. Reddy’s") reported that it named Akhil Ravi as CEO for its wholly-owned subsidiary Aurigene Pharmaceutical Services Ltd. (APSL) effective February 1, 2022 (Press release, Dr Reddy’s, FEB 1, 2022, View Source [SID1234607562]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Since joining Dr. Reddy’s in 2018 from McKinsey & Company, Akhil Ravi has served as Head of Strategy for Services and Active Pharmaceutical Ingredients (APIs), and headed the Sales of APIs in Europe. In addition, he has also had a brief stint as Plant Head. Akhil holds a BTech degree in Chemical Engineering from IIT Bombay and an MBA from the Indian School of Business (ISB).

"Akhil is very well prepared for this role. He was instrumental in growing our API business through product development and an improved service experience for our B2B customers through digital platforms. His strong background in customer service, sales, strategy, and management make him an ideal leader for Aurigene, and we look forward to his accomplishments in this new role." said Deepak Sapra, CEO of API and Services at Dr. Reddy’s, and Member of the Board at Aurigene.

Akhil Ravi said: "Aurigene Pharmaceutical Services is a dynamic partner for global pharma companies. With its integrated services from clinical research up to commercial manufacturing for small and large molecules, it is able to significantly speed up the journey of an NCE/NBE (New Chemical and Biological Entities) to the patient. I am very thrilled to join Aurigene and work with the team to serve innovative global pharma and biotech companies."

On February 1, 2022 Chimeric Therapeutics (ASX:CHM, "Chimeric"), a clinical-stage cell therapy company and the ASX leader in cell therapy, reported that it has signed a Sponsored Research Agreement with the University of Pennsylvania ("Penn") to support the continued research and development of CHM 2101, a novel 3rd generation CDH17 CAR T cell therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The research will be led by one of the inventors of CHM 2101, Xianxin Hua, MD, PhD. Dr Hua is a professor of Cancer Biology in Penn’s Perelman School of Medicine, and an investigator at the Abramson Family Cancer Research Institute.

The research will focus on furthering the development of CHM 2101 with preclinical studies in gastrointestinal cancers, enhancing the understanding of CHM 2101 through correlative studies and investigating CDH17 directed follow on candidates.

As part of the agreement, Chimeric has the first right of negotiation to license Penn intellectual property arising from the conduct of the sponsored research. "We are pleased to announce this research agreement as it reflects our shared commitment to the further research and development of CHM 2101 with Dr. Hua and the University of Pennsylvania," said Jennifer Chow, Chief Executive Officer of Chimeric Therapeutics.

"We are also thrilled with the progress we have made on driving this important therapy to clinic and are excited as the execution of this agreement will enhance our ability to move forward with that goal."

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper